The study found that 14% of U.S. adults lack adequate iron, while 15% have functional iron deficiency, where their bodies can't properly use the iron they have.

The new drug Cobenfy promises to revolutionize treatment for schizophrenia with its novel mechanism, the first of its kind in decades.